Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT Margin: 2010-2021

Historic EBIT Margin for Neurocrine Biosciences (NBIX) over the last 9 years, with Sep 2021 value amounting to 15.03%.

  • Neurocrine Biosciences' EBIT Margin rose 3217.00% to 15.03% in Q3 2021 from the same period last year, while for Sep 2021 it was 8.84%, marking a year-over-year decrease of 460.00%. This contributed to the annual value of 9.17% for FY2019, which is 99.00% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' EBIT Margin is 15.03%, which was down 30.84% from 21.74% recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' EBIT Margin peaked at 40.57% during Q3 2019, and registered a low of -903.99% during Q2 2017.
  • In the last 3 years, Neurocrine Biosciences' EBIT Margin had a median value of 19.37% in 2019 and averaged 8.94%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 90,208bps in 2018, then tumbled by 5,770bps in 2020.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' EBIT Margin stood at 12.52% in 2017, then skyrocketed by 411bps to 16.63% in 2018, then skyrocketed by 335bps to 19.98% in 2019, then slumped by 5,770bps to -17.14% in 2020, then surged by 3,217bps to 15.03% in 2021.
  • Its EBIT Margin was 15.03% in Q3 2021, compared to 21.74% in Q2 2021 and 13.31% in Q1 2021.